Mississippi Man Admits $51 Million Health Care Fraud Scheme Involving Durable Medical Equipment, Genetic Cancer Screening Tests, and Compounded Medications

NEWARK, N.J. – A Mississippi man who owned, operated, had financial interests in, or was affiliated with pharmacies, durable medical equipment (DME) companies, and a laboratory today admitted his role in a health care fraud scheme that caused losses to Medicare in excess of $51 million, Attorney for the United States Caroline Sadlowski announced.

Keaton Langston, 39, of Booneville, Mississippi, pleaded guilty before U.S. District Judge Michael E. Farbiarz in Newark federal court to an information charging him with conspiracy to commit health care fraud.

According to documents filed in the case and statements made in court:

Langston and others owned, operated, had financial interests in, or were affiliated with pharmacies, DME companies, and a laboratory that Langston and others used to defraud health care benefit programs by offering and paying kickbacks and bribes in exchange for doctors’ orders for DME, genetic cancer screening tests, and compounded medications. The pharmacies, DME companies, and laboratory submitted or caused the submission to Medicare of claims for reimbursement without regard to medical necessity, and sent a portion of the proceeds to others as payment for the doctors’ orders generated through the conspiracy. Langston and others concealed the payment of bribes, in part, by entering into sham contracts designed to make it appear that suppliers were engaged in and being paid for legitimate marketing and referral services based on the hours and expenses incurred or on a flat-rate basis.   

The pharmacies, DME companies, and laboratory billed Medicare and other health care benefit programs at approximately $51 million for tests and orders that were the product of the illicit scheme. Langston received approximately $10 million from these reimbursements.

The charge of conspiracy to commit health care fraud is punishable by a maximum of 10 years in prison and a fine of $250,000, or twice the gross gain or loss from the offense, whichever is greatest. Sentencing is scheduled for Oct. 1, 2024.

Attorney for the United States Sadlowski credited special agents of the FBI, under the direction of Special Agent in Charge James E. Dennehy in Newark; the Department of Health and Human Services-Office of Inspector General, under the direction of Special Agent in Charge Naomi Gruchacz; the U.S. Department of Defense, Office of the Inspector General, Defense Criminal Investigative Service, under the direction of Acting Special Agent in Charge Brian J. Solecki; and the U.S. Department of Veterans Affairs Office of Inspector General, under the direction of Special Agent in Charge Christopher F. Algieri with the investigation leading to the guilty plea.

The government is represented by Assistant U.S. Attorney Matthew Specht of the Special Prosecutions Division.